X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
NBL-001 (volasertib) is a PLK-1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of relapsed/refractory acute myelogenous leukemia.
Lead Product(s): Volasertib
Therapeutic Area: Oncology Product Name: NBL-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
The Merger will focus on developing new precision medicines through Notable’s proprietary Predictive Precision Medicines Platform. NBL-001 (volasertib) is derived from PPMP and is a highly potent PLK1 inhibitor inducing cell cycle arrest and apoptosis in cancer cells.
Lead Product(s): Volasertib
Therapeutic Area: Oncology Product Name: NBL-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Notable Labs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 16, 2023
Details:
The Merger will create a company developing new precision medicines through Notable’s proprietary Predictive Precision Medicines Platform (PPMP). NBL-001 (volasertib) is derived from PPMP and is a highly potent PLK1 inhibitor inducing cell cycle arrest and apoptosis in cancer cells.
Lead Product(s): Volasertib
Therapeutic Area: Oncology Product Name: NBL-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Notable stockholders Builders VC
Deal Size: $10.3 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 16, 2023
Details:
The Merger will create a clinical-stage therapeutic platform company developing new precision medicines through Notable’s proprietary PPMP. NBL-001 (volasertib) is derived from PPMP and is a highly potent PLK1 inhibitor inducing cell cycle arrest and apoptosis in cancer cells.
Lead Product(s): Volasertib
Therapeutic Area: Oncology Product Name: NBL-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: VBL Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 23, 2023
Details:
Notable’s lead asset derived from PPMP is NBL-001 (volasertib), a highly potent PLK1 inhibitor proven to induce cell cycle arrest and apoptosis in various cancer cells.
Lead Product(s): Volasertib
Therapeutic Area: Oncology Product Name: NBL-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Builders VC
Deal Size: $10.3 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 23, 2023
Details:
Under the terms of this agreement, Oncoheroes will retain the license for the development and commercialization of volasertib for pediatric cancers and continue its commitment towards childhood cancer.
Lead Product(s): Volasertib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oncoheroes Biosciences Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 11, 2021
Details:
Volasertib is a Polo-like kinase 1 (PLK-1) inhibitor with demonstrated activity in AML and other tumor types with significant unmet medical need. Company plan to fast-track volasertib’s development with phase 2/3 clinical trials in AML and other cancers.
Lead Product(s): Volasertib,Cytarabine
Therapeutic Area: Oncology Product Name: NBL-001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
